Gilead Sciences (GILD) Receivables - Net (2009 - 2026)

Gilead Sciences has reported Receivables - Net for 18 years, with the latest figure at $4.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 8.04% year-over-year to $4.7 billion; the trailing twelve-month figure through Mar 2026 stood at $4.7 billion (up 8.04% YoY), and the FY2025 full-year result was $5.9 billion, up 33.37% from the prior year.
• Receivables - Net for Q1 2026 stood at $4.7 billion, down from $5.9 billion in the prior quarter.
• The five-year high for Receivables - Net was $5.9 billion in Q4 2025, with the low at $3.8 billion in Q1 2022.
• Historically, Receivables - Net has averaged $4.7 billion across 5 years, with a median of $4.7 billion in 2023.
• The largest YoY upside for Receivables - Net was 33.37% in 2025 against a maximum downside of 20.48% in 2025.
• Gilead Sciences' Receivables - Net stood at $5.5 billion in 2022, then dropped by 14.71% to $4.7 billion in 2023, then dropped by 5.15% to $4.4 billion in 2024, then soared by 33.37% to $5.9 billion in 2025, then decreased by 19.58% to $4.7 billion in 2026.
• The last three Receivables - Net figures came in at $4.7 billion (Q1 2026), $5.9 billion (Q4 2025), and $5.1 billion (Q3 2025), per Business Quant data.